Construction, Characterization, and Immunogenicity of a Multigene Modified Vaccinia Ankara (MVA) Vaccine Based on HIV Type 1 Subtype C-Reference-Cited by-同舟云学术

Construction, Characterization, and Immunogenicity of a Multigene Modified Vaccinia Ankara (MVA) Vaccine Based on HIV Type 1 Subtype C

Published:2008-02 Issue:2 Volume:24 Page:195-206
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Burgers Wendy A.¹,Shephard Enid¹²,Monroe James E.³,Greenhalgh Trish³,Binder Anke¹,Hurter Etienne¹,Van Harmelen Joanne H.¹,Williamson Carolyn¹,Williamson Anna-Lise¹⁴

Affiliation:

1. Institute of Infectious Disease and Molecular Medicine and Division of Medical Virology, Department of Clinical Laboratory Sciences, University of Cape Town, Cape Town, South Africa.

2. MRC/UCT Liver Research Centre, University of Cape Town, Cape Town, South Africa.

3. Therion Biologics Corporation, Cambridge, Massachusetts.

4. National Health Laboratory Services, Groote Schuur Hospital, Cape Town, South Africa.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/aid.2007.0205

Reference52 articles.

1. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine.

2. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells.